Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review

Stavros Sfoungaristos, Vasileios Kourmpetis, Eleftherios Fokaefs, Petros Perimenis, Stavros Sfoungaristos, Vasileios Kourmpetis, Eleftherios Fokaefs, Petros Perimenis

Abstract

High-risk prostate cancer represents a pretentious clinical problem since a significant number of its patients will relapse and progress after radical prostatectomy. Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have been used in high-risk patients prior to radical prostatectomy. Even though the results regarding the prognostic surrogates are not significant, the effects on clinical and pathological outcomes are promising, while toxicity in most of the studies is in the expected field.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians. 2012;62:10–29.
    1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urologic Clinics of North America. 2001;28(3):555–565.
    1. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. International Journal of Radiation Oncology Biology Physics. 2003;57(4):915–928.
    1. D’Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. Journal of Clinical Oncology. 1999;17(1):168–172.
    1. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. Journal of the National Cancer Institute. 1998;90(10):766–771.
    1. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. Journal of Urology. 1998;160(6):2428–2434.
    1. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. Journal of the National Cancer Institute. 2009;101(18):1280–1283.
    1. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142.
    1. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007;110(6):1248–1254.
    1. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clinical Cancer Research. 2005;11(14):5233–5240.
    1. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. Journal of Urology. 2008;180(2):565–570.
    1. Mellado B, Font A, Alcaraz A, et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. British Journal of Cancer. 2009;101(8):1248–1252.
    1. Kim WY, Whang YE, Pruthi RS, et al. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urologic Oncology. 2011;29(6):608–613.
    1. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology. 2003;61(4):774–780.
    1. Prayer-Galetti T, Sacco E, Pagano F, et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU International. 2007;100(2):274–280.
    1. Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–327.
    1. Narita S, Tsuchiya N, Kumazawa T, et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World Journal of Surgical Oncology. 2012;10(1)
    1. Garzotto M, Higano CS, O’Brien C, et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer. 2010;116(7):1699–1708.
    1. Womble PR, VanVeldhuizen PJ, Nisbet AA. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. Journal of Urology. 2011;186:882–887.
    1. Friedman J, Dunn RL, Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. Journal of Urology. 2008;179(3):911–916.
    1. Ross RW, Galsky MD, Febbo P, et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012;118(19):4777–4784.
    1. Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. Journal of Urology. 2009;181(4):1672–1677.
    1. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. Journal of Urology. 2004;171(2):709–713.
    1. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001;57(2):281–285.
    1. Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, PierreTriozzi, Director RD. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clinical Cancer Research. 2008;14(10):3052–3059.
    1. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. Journal of Clinical Oncology. 2000;18(5):1050–1057.
    1. Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC. A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology. 2012;80(2):484.e17–484.e22.
    1. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European Urology. 2011;59(1):61–71.
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine. 2004;351(15):1502–1512.
    1. Vuky J, Porter C, Isacson C, et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–791.
    1. Mathew P, Pisters LL, Wood CG, et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. Journal of Urology. 2009;181(1):81–87.
    1. Ayala G, Yan J, Li R, et al. Bort6ezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clinical Cancer Research. 2008;14(22):7511–7518.
    1. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. European Urology. 2011;59(4):572–583.
    1. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. Journal of the National Cancer Institute. 2009;101(18):1280–1283.
    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Journal of Urology. 2002;167(2):948–952.
    1. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine. 2004;351(15):1513–1520.
    1. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of the National Cancer Institute. 2006;98(8):516–521.
    1. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of Clinical Oncology. 1999;17(8):2506–2513.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi